A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
NCT07416552
Colonic Diseases, Colorectal Neoplasms
Omaha, Nebraska, United States
View Trial DetailsNCT Number: NCT05787197
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.
Interested in participating?
Request Info18 year and older
All sexes
Observational
CHU Jean Minjoz, Besançon, France
Blood collection times according to specific clinical situations:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The patient will be included if:
Exclusion criteria
The patient will be excluded if:
Time frame: Up to 36 months
DFS is defined as the time from complete surgical resection (following first surgery if one-stage surgery or second surgery if two-stage strategy) to first documented event (relapse or death, whichever occurred first), or until last contact if no event occurs.
Time frame: Up to 4 years
EFS is defined as time between inclusion until the occurrence of an event: disease progression, relapse, disease progression, or death from any reason.
Time frame: Up to 4 years
OS is defined as the time between inclusion and death. Alive patients will be censored at the last date known to be alive, either during study treatment period or during follow-up period.
Time frame: Up to 4 years
TFS is defined as the time from initial surgery until the first unresectable recurrence or death from any cause or the date of the last follow-up, at which point data are censored.
Time frame: Up to 4 years
Prognostic value of ctDNA:
Time frame: Up to 4 years
Prognostic factor(s) for disease recurrence and survival in patients who undergo curative-intent resection of CRLM.
Time frame: Up to 4 years
To identify the clinical, biological, and pathological factors associated with the ctDNA level.
Contact information is provided by the study sponsor or research team.
Marie Line GARCIA, MD
CONTACT
Maximiliano GELLI, MD
CONTACT
GERCOR - Multidisciplinary Oncology Cooperative Group
Other
Circulating Tumor DNA in Patients With Colorectal Cancer Undergoing Curative-intent Surgery for Liver Metastases: Prospective, Multicenter, GERCOR Cohort
Acronym: CLIMES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07416552
Colonic Diseases, Colorectal Neoplasms
Omaha, Nebraska, United States
View Trial DetailsNCT06149481
Colonic Diseases, Colorectal Neoplasms
Bethesda, Maryland, United States
View Trial DetailsNCT01174121
Adnexal Diseases, Breast Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06820463
Colonic Diseases, Colorectal Neoplasms
Duarte, California, United States
View Trial Details